Mosaic ImmunoEngineering Inc. (CPMV) Research

Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health. The company's core product is MIE-101, a nanoparticle-based treatment sourced from the cowpea mosaic virus, which has demonstrated non-infectious characteristics in mice, dogs, and humans. Headquartered in Novato, California, the company commenced operations in 2020.

Market snapshot

Symbol
CPMV
Price
$0.67
Day change
0.00%
Market cap
$4.9M
P/E ratio
-7.15x
52-week range
0.31-1.05
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BetterLife Pharma Inc. (BETRF)
  • Bioxytran, Inc. (BIXT)
  • Burzynski Research Institute, Inc. (BZYR)
  • Curative Biotechnology, Inc. (CUBT)
  • Glow Lifetech Corp. (GLWLF)
  • NanoSphere Health Sciences Inc. (NSHSF)
  • PharmaTher Holdings Ltd. (PHRRF)
  • Quantum Genomics S.A. (QNNTF)

Recent insider activity

  • KING STEVEN W — J-Other (0 shares) on 2022-02-18
  • FELCYN GLORIA — J-Other (0 shares) on 2022-02-18
  • GARNICK ROBERT L — J-Other (0 shares) on 2022-02-18
  • BAFFI ROBERT — J-Other (0 shares) on 2022-02-18
  • Steinmetz Nicole Franziska — J-Other (0 shares) on 2022-02-18

Open Mosaic ImmunoEngineering Inc. (CPMV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.